Drug price regulator, the National Pharmaceutical Pricing Authority (NPPA) has fixed the ceiling price of 92 drug formulations used for treatment of cancer, hepatitis C, migraine and diabetes among others. The prices have been fixed/ revised under the Drug (Prices Control) Order (DPCO), 2013.
The authority has mentioned that out of total, the retail price of 72 scheduled formulations has been fixed, that of 9 has been revised. It has also revised the retail prices of 11 scheduled formulations. Under the Drugs (Prices Control) Order (DPCO) 2013, it fixes ceiling price of essential medicines of Schedule I based on simple average of all medicines in a particular therapeutic segment with sales of more than 1%.
In respect of medicines not under price control, manufacturers are allowed to increase the maximum retail price by 10% annually. Set up in 1997, NPPA has been entrusted with the task of fixation/revision of prices of pharma products, enforcement of provisions of DPCO and monitoring of prices of controlled and decontrolled drugs.
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: